Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 1, Pages 259
Publisher
MDPI AG
Online
2020-01-21
DOI
10.3390/jcm9010259
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
- (2018) Eugene Han et al. Frontiers in Endocrinology
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
- (2018) Eugene Han et al. Diabetes Therapy
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases
- (2017) Eugene Han et al. Diabetes & Metabolism Journal
- Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
- (2017) Kyung-Wan Min et al. Diabetes & Metabolism Journal
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
- (2016) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
- (2016) Eugene Han et al. MEDICINE
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
- (2016) Obesity Facts
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
- (2015) Christopher S. Kovacs et al. CLINICAL THERAPEUTICS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial Effects of Canagliflozin in Combination with Pioglitazone on Insulin Sensitivity in Rodent Models of Obese Type 2 Diabetes
- (2015) Yoshinori Watanabe et al. PLoS One
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Visceral Fat Accumulation Is Associated with Colorectal Cancer in Postmenopausal Women
- (2014) Jee-Yon Lee et al. PLoS One
- A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
- (2014) Chang Hee Jung et al. Diabetes & Metabolism Journal
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population
- (2013) Young Eun Chon et al. LIVER INTERNATIONAL
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
- (2009) Anna Kotronen et al. GASTROENTEROLOGY
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now